Potential clinical applications of vasoactive intestinal peptide: A selected update

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 18, Issue 4, 2004, Pages 623-640

  Gozes, Illana ^a   Furman, Sharon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

PAC1; VIP; VIP analogs; VPAC1; VPAC2

Indexed keywords

4 HYDROXYTAMOXIFEN; ACETYLCHOLINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BAY 55 9837; CHEMOKINE; CISPLATIN; CORTICOTROPIN; DOXORUBICIN; ESTRADIOL; FULVESTRANT; GEMCITABINE; HYDROCORTISONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; IRINOTECAN; JV 1 52; MESSENGER RNA; NAVELBINE; NEUROTENSIN[6-11]VASOACTIVE INTESTINAL POLYPEPTIDE[7-28]; OMAPATRILAT; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE[6-28]; GASTROINTESTINAL AGENT; NEUROPROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN DISEASE; BREAST CANCER; CANCER; CANCER GROWTH; CANCER INHIBITION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROHN DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENDOCRINE CELL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; MAXIMUM TOLERATED DOSE; NERVE CELL DIFFERENTIATION; NEUROENDOCRINE SYSTEM; NEUROPROTECTION; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CARDIOVASCULAR SYSTEM; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; GASTROINTESTINAL AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SIGNAL TRANSDUCTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 16644402755     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2004.08.006     Document Type: Review

References (123)

1. S.I. Said V. Mutt A peptide fraction from lung tissue with prolonged peripheral vasodilator activity Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum 107 1969 51-56
2. S.I. Said V. Mutt Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon European Journal of Biochemistry 28 1972 199-204
3. I. Gozes M. Fridkin J.M. Hill D.E. Brenneman Pharmaceutical VIP: prospects and problems Current Medicinal Chemistry 6 1999 1019-1034
4. I. Gozes S. Furman VIP and drug design Current Pharmaceutical Design 9 2003 483-494
5. C. Tourrel D. Bailbe M. Lacorne et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 Diabetes 5 2002 1443-1452
6. A. Arimura Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems Japanese Journal of Physiology 48 1998 301-331
7. K. Tatemoto V. Mutt Chemical determination of polypeptide hormones Proceedings of the National Academy of Sciences of the United States of America 75 1978 4115-4119
8. K. Tatemoto V. Mutt Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon-secretin family Proceedings of the National Academy of Sciences of the United States of America 78 1981 6603-6607
9. Y. Yiangou S.J. Williams A.E. Bishop et al. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome Journal of Clinical Endocrinology and Metabolism 64 1987 131-139
10. M. Bodner M. Fridkin I. Gozes Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome Proceedings of the National Academy of Sciences of the United States of America 82 1985 3548-3551
11. M. Laburthe A. Couvineau J.C. Marie VPAC receptors for VIP and PACAP Receptors Channels 8 2002 137-153
12. A.J. Harmar A.I. Arimura I. Gozes et al. International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide Pharmacological Reviews 50 1998 265-270
13. A.J. Harmar Family-B G-protein-coupled receptors Genome Biology 2 2001 3013
14. S.P. Sreedharan D.R. Patel J.X. Huang E.J. Goetzl Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor Biochemical and Biophysical Research Communications 193 1993 546-553
15. T.B. Usdin T.I. Bonner E. Mezey Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions Endocrinology 135 1994 2662-2680
16. M. Delgado C. Martinez M.C. Johnson et al. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes Journal of Neuroimmunology 68 1996 27-38
17. Y. Wei S. Mojsov Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology Journal of Neuroendocrinology 8 1996 811-817
18. A.J. Harmar W.J. Sheward C.F. Morrison et al. Distribution of the VPAC2 receptor in peripheral tissues of the mouse Endocrinology 145 2004 1203-1210
19. J. Voice S. Donnelly G. Dorsam et al. cMaf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide Journal of Immunology 172 2004 7289-7296
20. D. Spengler C. Waeber C. Pantaloni et al. Differential signal transduction by five splice variants of the PACAP receptor Nature 365 1993 170-175
21. H. Hashimoto H. Nogi K. Mori et al. Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: An in situ hybridization study Journal of Comparative Neurology 371 1996 567-577
22. K. Moller F. Sundler Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla Regulatory Peptides 63 1996 129-139
23. N. Zeng T. Kang R.M. Lyu et al. The pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: Evidence by immunocytochemistry and RT-PCR Annals of the New York Academy of Sciences 865 1998 147-156
24. M. Miampamba P.M. Germano S. Arli et al. Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons Regulatory Peptides 105 2002 145-154
25. D.A. McCulloch C.J. MacKenzie M.S. Johnson et al. Additional signals from VPAC/PAC family receptors Biochemical Society Transactions 30 2002 441-446
26. M. Quik L.L. Iversen S.R. Bloom Effect of vasoactive intestinal peptide (VIP) and other peptides on cAMP accumulation in rat brain Biochemical Pharmacology 27 1978 2209-2213
27. Y. Yajima Y. Akita T. Saito S. Kawashima VIP induces the translocation and degradation of the alpha subunit of Gs protein in rat pituitary GH4C1 cells Journal of Biochemistry (Tokyo) 123 1998 1024-1030
28. S. Paul Decreased selectivity of vasoactive intestinal peptide receptors by GTP Biochemical Pharmacology 38 1989 699-702
29. V. Lelievre N. Pineau J. Du et al. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase Journal of Biological Chemistry 273 1998 19685-19690
30. D.A. McCulloch E.M. Lutz M.S. Johnson et al. ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant Molecular Pharmacology 59 2001 1523-1532
31. K.S. Murthy G.M. Makhlouf Differential regulation of phospholipase A2 (PLA2)-dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases. Inhibitory phosphorylation of PLA2 by cyclic nucleotide-dependent protein kinases Journal of Biological Chemistry 273 1998 34519-34526
32. T.R. Koch S.R. Michener V.L. Go Plasma vasoactive intestinal polypeptide concentration determination in patients with diarrhea Gastroenterology 100 1991 99-106
33. M. Hejna G. Hamilton T. Brodowicz et al. Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract Anticancer Research 21 2001 1183-1187
34. N. Umemoto M. Kakurai H. Okazaki et al. Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis Journal of Dermatological Science 31 2003 161-164
35. V. Petkov W. Mosgoeller R. Ziesche et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension Journal of Clinical Investigation 111 2003 1339-1346
36. X. Wang Z. Gong K. Wu et al. Gastrointestinal dysmotility in patients with acute pancreatitis Journal of Gastroenterology and Hepatology 18 2003 57-62
37. K. Calhoun S. Toth-Fejel J. Cheek R. Pommier Serum peptide profiles in patients with carcinoid tumors American Journal of Surgery 186 2003 28-31
38. S.K. Kassim M. El Touny M. El Guinaidy et al. Serum nitrates and vasoactive intestinal peptide in patients with gastroesophageal reflux disease Clinical Biochemistry 35 2002 641-646
39. M.S. O'Dorisio M. Hauger T.M. O'Dorisio Age-dependent levels of plasma neuropeptides in normal children Regulatory Peptides 109 2002 189-192
40. V. Chongsrisawat S. Ampai P. Chotivitayatarakorn et al. Relationship between vasoactive intestinal peptide and intrapulmonary vascular dilatation in children with various liver diseases Acta Paediatrica 92 2003 1411-1414
41. I. Gozes D.E. Brenneman G. Lilling et al. Neuropeptide-regulation of mitosis Annals of the New York Academy of Sciences 739 1994 253-261
42. J.C. Reubi U. Laderach B. Waser et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin Cancer Research 60 2000 3105-3112
43. B. Madsen B. Georg M.W. Madsen J. Fahrenkrug Estradiol down regulates expression of vasoactive intestinal polypeptide receptor type-1 in breast cancer cell lines Molecular and Cellular Endocrinology 172 2001 203-211
44. S.R. Bloom J.M. Polak A.G.E. Pearse Vasoactive intestinal peptide and watery-diarrhea syndrome Lancet 2 1973 14-16
45. S.K. Park M.S. O'Dorisio T.M. O'Dorisio Vasoactive intestinal polypeptide-secreting tumours: Biology and therapy Baillieres Clinical Gastroenterology 10 1996 673-696
46. I. Gozes A. Davidson M. Draui T.W. Moody The VIP gene is expressed in non-small cell lung cancer cell lines Biomedical Research 13 1992 37-39
47. T.W. Moody J.M. Hill R.T. Jensen VIP as a trophic factor in the CNS and cancer cells Peptides 24 2003 163-177
48. G. Lilling Y. Wollman M.N. Goldstein et al. Inhibition of human neuroblastoma growth by a specific VIP antagonist Journal of Molecular Neuroscience 5 1995 231-239
49. M.C. Fruhwald M.S. O'Dorisio S.L. Cottingham et al. Neuropeptides in developmental tumors of the central and peripheral nervous system Annals of the New York Academy of Sciences 865 1998 420-426
50. Y. Wollman G. Lilling M.N. Goldstein et al. Vasoactive intestinal peptide: A growth promoter in neuroblastoma cells Brain Research 624 1993 339-341
51. A. Sharma J. Walters Y. Gozes et al. Vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells Journal of Molecular Neuroscience 17 2001 331-339
52. A. Levy R. Gal R. Granoth et al. In vitro and in vivo treatment of colon cancer by VIP antagonists Regulatory Peptides 109 2002 127-133
53. T.W. Moody J. Dudek H. Zakowicz et al. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice Life Sciences 74 2004 1345-1357
54. I. Gozes M. Fridkin D.E. Brenneman A VIP hybrid antagonist: From developmental neurobiology to clinical applications Cellular and Molecular Neurobiology 15 1995 675-687
55. T.W. Moody R.T. Jensen M. Fridkin I. Gozes (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist Journal of Molecular Neuroscience 18 2002 29-35
56. I. Gozes G. Lilling R. Glazer et al. Superactive lipophilic peptides discriminate multiple VIP receptors Journal of Pharmacology and Experimental Therapeutics 273 1995 161-167
57. T.W. Moody J. Walters M. Casibang et al. VPAC1 receptors and lung cancer Annals of the New York Academy of Sciences 921 2000 26-32
58. E. Gelber R. Granoth M. Fridkin et al. Lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines Cancer 92 2001 2172-2180
59. H. Zia J. Leyton M. Casibang et al. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines Life Sciences 66 2000 379-387
60. T.W. Moody J. Leyton D. Chan et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells Breast Cancer Research and Treatment 68 2001 55-64
61. A. Plonowski J.L. Varga A.V. Schally et al. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity International Journal of Cancer 98 2002 624-629
62. T.W. Moody G. Czerwinski N.I. Tarasova C.J. Michejda VIP-ellipticine derivatives inhibit the growth of breast cancer cells Life Sciences 71 2002 1005-1014
63. K. Maruno S.I. Said Small-cell lung carcinoma: Inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody Life Sciences 52 1993 PL267-PL271
64. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocrine Reviews 24 2003 389-427
65. G. Riccabona C. Decristoforo Peptide targeted imaging of cancer Cancer Biotherapy and Radiopharmaceuticals 18 2003 675-687
66. D. Hollander Inflammatory bowel diseases and brain-gut axis Journal of Physiology and Pharmacology 54 supplement 4 2003 183-190
67. J.K. Voice C. Grinninger Y. Kong et al. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice Journal of Immunology 170 2003 308-314
68. C. Abad C. Martinez M.G. Juarranz et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease Gastroenterology 124 2003 961-971
69. N.S. Joo T. Irokawa J.V. Wu et al. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands Journal of Biological Chemistry 277 2002 50710-50715
70. M. Delgado R.P. Gomariz C. Martinez et al. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: Role in lethal endotoxic shock European Journal of Immunology 30 2000 3236-3246
71. M. Delgado C. Abad C. Martinez et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease Nature Medicine 7 2001 563-568
72. A.D. Foey S. Field S. Ahmed et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: Implications for rheumatoid arthritis Arthritis Research and Therapy 5 2003 R317-R328
73. I. Gozes Y. Shani W.H. Rostene Developmental expression of the VIP-gene in brain and intestine Brain Research 388 1987 137-148
74. D.E. Brenneman L.E. Eiden Vasoactive intestinal peptide and electrical activity influence neuronal survival Proceedings of the National Academy of Sciences of the United States of America 83 1986 1159-1162
75. I. Gozes A. Bardea A. Reshef et al. Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide Proceedings of the National Academy of Sciences of the United States of America 93 1996 427-432
76. I. Gozes O. Perl E. Giladi et al. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design Proceedings of the National Academy of Sciences of the United States of America 96 1999 4143-4148
77. J.R. Glowa L.V. Panlilio D.E. Brenneman et al. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist Brain Research 570 1992 49-53
78. I. Gozes J. Glowa D.E. Brenneman et al. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene Journal of Molecular Neuroscience 4 1993 185-193
79. D.E. Brenneman I. Gozes A femtomolar-acting neuroprotective peptide Journal of Clinical Investigation 97 1996 2299-2307
80. M. Bassan R. Zamostiano A. Davidson et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide Journal of Neurochemistry 72 1999 1283-1293
81. I. Gozes R. Zamostiano A. Pinhasov et al. A novel VIP responsive gene. Activity dependent neuroprotective protein Annals of the New York Academy of Sciences 921 2000 115-118
82. I. Gozes I. Divinsky I. Pilzer et al. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division Journal of Molecular Neuroscience 20 2003 315-322
83. I. Divinski L. Mittelman I. Gozes A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication Journal of Biological Chemistry 279 2004 28531-28538
84. O. Blondel C. Collin W.J. McCarran et al. A glia-derived signal regulating neuronal differentiation Journal of Neuroscience 20 2000 8012-8020
85. D.E. Brenneman T.M. Phillips J. Hauser et al. Complex array of cytokines released by vasoactive intestinal peptide Neuropeptides 37 2003 111-119
86. M. Delgado D. Ganea Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma Federation of American Societies for Experimental Biology Journal 17 2003 1922-1924
87. D. Offen Y. Sherki E. Melamed et al. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease Brain Research 854 2000 257-262
88. R. Eilam A. Davidson I. Gozes M. Segal Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus Hippocampus 9 1999 534-541
89. P. Gressens L. Besse P. Robberecht et al. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives Journal of Pharmacology and Experimental Therapeutics 288 1999 1207-1213
90. P. Gressens J.M. Hill I. Gozes et al. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos Nature 362 1993 155-158
91. P. Gressens J.M. Hill B. Paindaveine et al. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse Journal of Clinical Investigation 94 1994 2020-2027
92. S.J. Servoss S.J. Lee G. Gibney et al. IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth Endocrinology 142 2001 3348-3353
93. A. Pinhasov S. Mandel A. Torchinsky et al. Activity-dependent neuroprotective protein: A novel gene essential for brain formation Brain Research. Developmental Brain Research 144 2003 83-90
94. K.B. Nelson J.K. Grether L.A. Croen et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation Annals of Neurology 49 2001 597-606
95. E. Adeghate A.S. Ponery A.K. Sharma et al. Diabetes mellitus is associated with a decrease in vasoactive intestinal polypeptide content of gastrointestinal tract of rat Archives of Physiology and Biochemistry 109 2001 246-251
96. M. Tsutsumi T.H. Claus Y. Liang et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes Diabetes 51 2002 1453-1460
97. M.A. Asnicar A. Koster M.L. Heiman et al. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate Endocrinology 143 2002 3994-4006
98. R. Avidor R. Eilam R. Malach I. Gozes VIP-mRNA is increased in hypertensive rats Brain Research 503 1989 304-307
99. R.J. Henning D.R. Sawmiller Vasoactive intestinal peptide: cardiovascular effects Cardiovascular Research 49 2001 27-37
100. O. Saetrum Opgaard M. Knutsson R. de Vries et al. Vasoactive intestinal peptide has a direct positive inotropic effect on isolated human myocardial trabeculae Clinical Science (London) 101 2001 637-643
101. S. Gunaydin Y. Imai Y. Takanashi et al. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: A comparative study with isoproteronol and nitroglycerine Cardiovascular Surgery 10 2002 138-145
102. P. Lucia S. Caiola A. Coppola et al. Vasoactive intestinal peptide (VIP): A new neuroendocrine marker of clinical progression in chronic heart failure? Clinical Endocrinology (Oxford) 59 2003 723-727
103. V.Z. Ye G. Hodge J.L. Yong K.A. Duggan Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension European Journal of Pharmacology 485 2004 235-242
104. S.R. Bornstein A. Haidan M. Ehrhart-Bornstein Cellular communication in the neuro-adrenocortical axis: Role of vasoactive intestinal polypeptide (VIP) Endocrine Research 22 1996 819-829
105. V.J. Cobb B.C. Williams J.I. Mason S.W. Walker Direct stimulation of cortisol secretion from the human NCI H295 adrenocortical cell line by vasoactive intestinal polypeptide Journal of Hypertension 15 1997 1735-1738
106. A. Haidan U. Hilbers S.R. Bornstein M. Ehrhart-Bornstein Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP) Peptides 19 1998 1511-1517
107. M.R. Nicol V.J. Cobb B.C. Williams et al. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors Journal of Molecular Endocrinology 32 2004 869-877
108. V.S. Fang C.C. Juan Y.P. Hsu et al. The stimulatory effect of vasoactive intestinal peptides on the cortisol production of guinea pig zona fasciculata cells: An extra-ACTH regulatory model of the adrenocortical function Chinese Journal of Physiology 44 2001 73-79
109. G. Mazzocchi L.K. Malendowicz P. Rebuffat et al. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland Journal of Clinical Endocrinology and Metabolism 87 2002 2575-2580
110. H. Watanobe T. Tamura A suppressive effect of dexamethasone (DEX) on adrenocorticotropin (ACTH) response to vasoactive intestinal peptide (VIP) in Cushing's disease: A parallel modulation by DEX of ACTH responses to VIP and corticotropin-releasing hormone Neuropeptides 31 1997 35-40
111. J.A. Balsa F. Sanchez-Franco F. Pazos et al. Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: autocrine and/or paracrine action of vasoactive intestinal peptide Neuroendocrinology 68 1998 326-333
112. M. Egli R. Bertram M.T. Sellix M.E. Freeman Rhythmic secretion of prolactin in rats: Action of oxytocin coordinated by vasoactive intestinal polypeptide of suprachiasmatic nucleus origin Endocrinology 145 2004 3386-3394
113. A. Tohei K. Taya G. Watanabe J.L. Voogt Hypothyroidism increases prolactin secretion and decreases the intromission threshold for induction of pseudopregnancy in adult female rats Physiology and Behavior 69 2000 391-397
114. A. Tohei Studies on the functional relationship between thyroid, adrenal and gonadal hormones Journal of Reproduction and Development 50 2004 9-20
115. W. Rostene M.N. Montagne M. Dussaillant I. Gozes Steroid regulation of vasoactive intestinal peptide (VIP) Stress 2 1997 79-90
116. L.J. Chew Z.D. Burke H. Morgan et al. Transcription of the vasoactive intestinal peptide gene in response to glucocorticoids: Differential regulation of alternative transcripts is modulated by a labile protein in rat anterior pituitary Molecular and Cellular Endocrinology 130 1997 83-91
117. I. Gozes H. Werner M. Fawzi et al. Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus Journal of Molecular Neuroscience 1 1989 55-61
118. R. Granoth M. Fridkin I. Gozes VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes FEBS Letters 475 2000 78-83
119. R. Granoth M. Fridkin S. Rubinraut I. Gozes VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: The human keratinocyte as a model FEBS Letters 475 2000 71-77
120. I. Gozes A. Reshef D. Salah S. Rubinraut M. Fridkin Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment Endocrinology 134 1994 2121-2125
121. I. Gozes M. Fridkin A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model Journal of Clinical Investigation 90 1992 810-814
122. O. Ashur-Fabian E. Giladi D.E. Brenneman I. Gozes Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides Journal of Molecular Neuroscience 9 1997 211-222
123. O. Ashur-Fabian O. Perl G. Lilling et al. SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival Peptides 20 1999 629-633